Global Connected Drug Delivery Devices Market Forecast.
Global Connected Drug Delivery Devices Market Size – By Device Type, By Technology, By Application and By End Use- Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Feb-2026 | Report ID: MEDE2613 | Pages: 1 - 159 | Formats*: |
| Category : Medical Devices | |||
According to SPER Market Research, the Global Connected Drug Delivery Devices Market is estimated to reach USD 7.91 billion by 2034 with a CAGR 32.05%.
Introduction and Overview
The report includes an in-depth analysis of the Global Connected Drug Delivery Devices Market, including market size and trends, product mix, Applications, and supplier analysis.
The global connected drug delivery devices market is experiencing rapid expansion, fuelled by the integration of advanced technologies like Bluetooth, Wi-Fi, and IoT into medical devices for superior medication management. Valued at approximately USD 491.2 million in 2024, this sector is projected to advance at a robust 32.05% CAGR through 2034, driven by rising needs for real-time patient monitoring and adherence in chronic disease treatment. Innovations such as smart inhalers and insulin pens enable seamless data sharing with healthcare providers, enhancing outcomes in remote settings and transforming pharmaceutical delivery.
By Device Type:
The global connected drug delivery devices market highlights two key device categories: connected sensors and integrated devices. Integrated devices lead the sector, driven by their seamless fusion of drug administration and digital tracking, ideal for home-based care and chronic conditions. These all-in-one solutions boost patient compliance via real-time data to apps and providers. Connected sensors, as adaptable add-ons to traditional tools like inhalers and pens, enable retrofitting for monitoring without hardware overhauls.
By Technology:
In the global connected drug delivery devices market, Bluetooth technology leads prominently, thanks to its effortless integration with smartphones and robust support for ongoing patient monitoring. Near Field Communication offers efficient, contactless data exchange for precise dosing, while Wi-Fi provides expansive connectivity for comprehensive health platforms. These innovations empower users with adherence reminders, real-time insights, and remote oversight, transforming chronic disease management. As healthcare shifts toward digital solutions, Bluetooth's versatility ensures its top position, driving enhanced outcomes without reliance on complex setups.
By Application:
In the realm of Global connected drug delivery devices, applications span anaphylaxis management with intelligent injectors, respiratory therapies via advanced inhalers, cardiovascular treatments through monitored systems, diabetes control with linked pens and pumps, hormone replacement options, and additional uses. Respiratory solutions command the forefront, propelled by urgent needs for effective chronic airway disease handling. These innovations empower patients with instant feedback, dosage precision, and seamless provider connectivity, fostering better outcomes amid surging lifestyle-related ailments and a shift toward home-based care.
By End Use:
Global Connected drug delivery devices are transforming healthcare delivery across various settings, notably hospitals, clinics, home care environments, and other facilities. Among these, home care settings lead the market, fuelled by the growing preference for patient-centric, remote monitoring solutions that promote independence, especially for chronic condition management. These devices enable seamless data sharing with providers, enhancing adherence and outcomes without frequent facility visits. Clinics and hospitals support structured care, while other end uses address specialized needs, collectively driving innovation in accessible, tech-enabled therapy administration.
Regional Insights:
In North America, the U.S. market for connected drug delivery devices is set for robust expansion, fuelled by a post-COVID telehealth boom that has spiked remote monitoring needs. Regulatory backing from the FDA's Digital Health Center of Excellence, including swift approvals for AI/ML-integrated devices, creates a favourable environment for innovation and adoption. Europe's UK segment promises strong growth, driven by rising chronic disease rates like diabetes, which demand better adherence tools. The MHRA's streamlined regulations and updated surveillance rules position the nation as a medtech leader. In the Asia Pacific, Japan's aging population—now with a record share of octogenarians—boosts demand for user-friendly devices supporting home-based chronic care through advanced data analytics and remote features. Middle East and Africa's Saudi Arabia market anticipates notable advances amid surging diabetes and cardiovascular burdens, with the SFDA's evolving digital health frameworks speeding device approvals and deployment.
Market Competitive Landscape:
The Global Connected Drug Delivery Devices Market is highly consolidated Some of the market key players are Adherium, Aptar Pharma, AstraZeneca, Becton Dickinson and Company, Bigfoot Biomedical, Cohero Health, Eli Lilly and Company, Insulet Corporation, Novartis, Novo Nordisk, Phillips Medisize, Propeller Health, Teva Pharmaceuticals, West Pharmaceutical Services, and Ypsomed
Recent Developments:
- In January 2020, Aptar Pharma partnered with Lupin Limited to introduce ADHERO, India's pioneering smart add-on for metered-dose inhalers (MDIs). This device helps patients with chronic respiratory issues monitor usage and boost therapy adherence, bolstering Aptar Pharma's role in the expanding connected drug delivery sector and aiding better patient results.
- In May 2020, Propeller Health secured U.S. FDA 510(k) clearance to link Symbicort Inhaler users to its digital platform, broadening services, increasing patient involvement, and enhancing outcomes for respiratory condition management.
Scope of the report:
| Report Metric | Details |
|---|---|
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Device Type, By Technology, By Application, By End Use |
| Regions covered | North America, Latin America, Asia-Pacific,Europe, the Middle East & Africa |
| Companies Covered | Adherium, Aptar Pharma, AstraZeneca, Becton Dickinson and Company, Bigfoot Biomedical, Cohero Health, Eli Lilly and Company, Insulet Corporation, Novartis, Novo Nordisk, Phillips Medisize, Propeller Health, Teva Pharmaceuticals, West Pharmaceutical Services, Ypsomed |
Key Topics Covered in the Report
- Global Connected Drug Delivery Devices Market Size (FY’2021-FY’2034)
- Overview of the Global Connected Drug Delivery Devices Market
- Segmentation of the Global Connected Drug Delivery Devices Market by Device Type (Connected sensors, Integrated devices)
- Segmentation of the Global Connected Drug Delivery Devices Market by Technology (Bluetooth, Near Field Communication, Wi-Fi)
- Segmentation of the Global Connected Drug Delivery Devices Market by Application (Anaphylaxis, Respiratory, Cardiovascular, Diabetes, Hormone replacement, and other applications)
- Segmentation of the Global Connected Drug Delivery Devices Market by End Use (Hospitals, Clinics, Home care settings, other end uses)
- Statistical Snap of Global Connected Drug Delivery Devices Market
- Expansion Analysis of the Global Connected Drug Delivery Devices Market
- Problems and Obstacles in the Global Connected Drug Delivery Devices Market
- Competitive Landscape in the Global Connected Drug Delivery Devices Market
- Details on Current Investment in the Global Connected Drug Delivery Devices Market
- Competitive Analysis of the Global Connected Drug Delivery Devices Market
- Prominent Players in the Global Connected Drug Delivery Devices Market
- SWOT Analysis of the Global Connected Drug Delivery Devices Market
- Global Connected Drug Delivery Devices Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1 Scope of the report1.2 Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary Data2.1.2 Primary Data2.1.3 SPER’s internal Database2.1.4 Primary insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1 Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers4.1.2 Restraints4.1.3 Opportunities4.1.4 Challenges
5. Market variable and outlook
5.1 SWOT Analysis
5.1.1 Strengths5.1.2 Weaknesses5.1.3 Opportunities5.1.4 Threats
5.2 PESTEL Analysis
5.2.1 Political Landscape5.2.2 Economic Landscape5.2.3 Social Landscape5.2.4 Technological Landscape5.2.5 Environmental Landscape
5.2.6 Legal Landscape
5.3 PORTER’s Five Forces5.4 Heat Map Analysis
6. Competitive Landscape
6.1. Global Connected Drug Delivery Devices Market Manufacturing Base Distribution, Sales Area, Product Type6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Connected Drug Delivery Devices Market
7. Global Connected Drug Delivery Devices Market, By Device Type, (USD Million) 2021-2034
7.1 Connected sensors7.1.1 Connected inhalation sensors7.1.2 Connected injectable sensors7.2 Integrated devices7.2.1 Integrated inhalation devices7.2.2 Integrated injectable devices
8. Global Connected Drug Delivery Devices Market, By Technology, (USD Million) 2021-2034
8.1 Bluetooth8.2 Near field communication8.3 Wi-Fi
9. Global Connected Drug Delivery Devices Market, By Application, (USD Million) 2021-2034
9.1 Anaphylaxis9.2 Respiratory9.3 Cardiovascular9.4 Diabetes9.5 Hormone replacement9.6 Other applications
10. Global Connected Drug Delivery Devices Market, By End Use, (USD Million) 2021-2034
10.1 Hospitals10.2 Clinics10.3 Home care settings10.4 Other end use
11. Global Connected Drug Delivery Devices Market, (USD Million) 2021-2034
11.1 Global Connected Drug Delivery Devices Market Size and Market Share
12. Global Connected Drug Delivery Devices Market, By Region, 2021-2034 (USD Million)
12.1 Asia-Pacific
12.1.1 Australia12.1.2 China12.1.3 India12.1.4 Japan12.1.5 South Korea12.1.6 Rest of Asia-Pacific
12.2 Europe
12.2.1 France12.2.2 Germany12.2.3 Italy12.2.4 Spain12.2.5 United Kingdom12.2.6 Rest of Europe
12.3 Middle East and Africa
12.3.1 Kingdom of Saudi Arabia12.3.2 United Arab Emirates12.3.3 Qatar12.3.4 South Africa12.3.5 Egypt12.3.6 Morocco12.3.7 Nigeria12.3.8 Rest of Middle-East and Africa
12.4 North America
12.4.1 Canada12.4.2 Mexico12.4.3 United States12.4.4 Rest of North America
12.5 Latin America
12.5.1 Argentina12.5.2 Brazil12.5.3 Rest of Latin America
13. Company Profile
13.1 Adherium
13.1.1 Company details13.1.2 Financial outlook13.1.3 Product summary13.1.4 Recent developments
13.2 Aptar Pharma
13.2.1 Company details13.2.2 Financial outlook13.2.3 Product summary13.2.4 Recent developments
13.3 AstraZeneca
13.3.1 Company details13.3.2 Financial outlook13.3.3 Product summary13.3.4 Recent developments
13.4 Becton Dickinson and Company
13.4.1 Company details13.4.2 Financial outlook13.4.3 Product summary13.4.4 Recent developments
13.5 Bigfoot Biomedical
13.5.1 Company details13.5.2 Financial outlook13.5.3 Product summary13.5.4 Recent developments
13.6 Cohero Health
13.6.1 Company details13.6.2 Financial outlook13.6.3 Product summary13.6.4 Recent developments
13.7 Eli Lilly and Company
13.7.1 Company details13.7.2 Financial outlook13.7.3 Product summary13.7.4 Recent developments
13.8 Insulet Corporation
13.8.1 Company details13.8.2 Financial outlook13.8.3 Product summary13.8.4 Recent developments
13.9 Novartis
13.9.1 Company details13.9.2 Financial outlook13.9.3 Product summary13.9.4 Recent developments
13.10 Novo Nordisk
13.10.1 Company details13.10.2 Financial outlook13.10.3 Product summary13.10.4 Recent developments
13.11 Phillips Medisize
13.11.1 Company details13.11.2 Financial outlook13.11.3 Product summary13.11.4 Recent developments
13.12 Propeller Health
13.12.1 Company details13.12.2 Financial outlook13.12.3 Product summary13.12.4 Recent developments
13.13 Teva Pharmaceuticals
13.13.1 Company details13.13.2 Financial outlook13.13.3 Product summary13.13.4 Recent developments
13.14 West Pharmaceutical Services
13.14.1 Company details13.14.2 Financial outlook13.14.3 Product summary13.14.4 Recent developments
13.15 Ypsomed
13.15.1 Company details13.15.2 Financial outlook13.15.3 Product summary13.15.4 Recent developments
13.16 Others
14. Conclusion
15. List Of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
